

PROGRAMME

FRIDAY 10.10.2025

12:00 – 15:30 WORKSHOP

Heart Valves in Focus – Modern Transcatheter Therapies in Everyday Clinical Practice / Zastawki pod kontrolą – nowoczesne terapie przezcewnikowe w codziennej praktyce klinicznej

Sesja 1: Przełom w leczeniu stenozы aortalnej – co każdy lekarz powinien wiedzieć o TAVI

Prowadzenie: Zenon Huczek, Michał Hawranek

12.00 – 12.15 TAVI – od kwalifikacji, poprzez zabieg, do wypisu (live-in-a-box)

12.15 – 12.30 Pacjent z bioprotezą aortalną, jak postępować?

12.30 – 13:00 Symulatory

Sesja 2: Przezcewnikowe leczenie niedomykalności mitralnej – szansa dla chorych wysokiego ryzyka

Prowadzenie: Wojciech Wojakowski, Piotr Scisło

13.00 – 13.15 Obraz istotnej niedomykalności mitralnej w badaniu echokardiograficznym – kiedy i kogo skierować do oceny pod kątem naprawy brzeg-do-brzegu (M-TEER)

13.15 – 13.30 M-TEER – od kwalifikacji, poprzez zabieg, do wypisu. Co jest ważne w opiece ambulatoryjnej?

13.30 – 13:45 Nowe możliwości – implantacja bioprotez u chorych ze zdegenerowaną zastawką chirurgiczną i natywną niedomykalnością mitralną (TMVR)

13:45 – 14:15 Symulatory

Sesja 3: Nowe możliwości w terapii niedomykalności trójdzielnej – koniec zapomnianej zastawki

Prowadzenie: Marek Grygier, Adam Rdzanek

14.15 – 14.30 Obraz istotnej niedomykalności trójdzielnej w badaniu echokardiograficznym – kiedy i kogo skierować do oceny pod kątem naprawy brzeg-do-brzegu (T-TEER) oraz do przeznaczeniowej wymiany zastawki trójdzielnej (TTVR)

14.30 – 14.45 T-TEER – od kwalifikacji, poprzez zabieg, do wypisu. Co jest ważne w opiece ambulatoryjnej?

14.45 – 15.00 Nowości w leczeniu niedomykalności trójdzielnej (TTVR)

15:00 – 15:30 Symulatory

→ Workshop in Polish / Warsztat w j. polskim

Sponsored session/ Sesje sponsorowane

12:00 – 15:00 WORKSHOP

Modern PCI Strategies in Clinical Practice – From Imaging to Optimization of Coronary Procedures: An Interactive Workshop / Nowoczesne strategie PCI w praktyce klinicznej – od obrazowania po optymalizację zabiegów wieńcowych – warsztat interaktywny

Wprowadzenie i cele warsztatu

Wykłady eksperckie (5 × 8 min)

Prowadzenie: Marta Kałużna-Oleksy



12:05 Bioadaptor – nowe możliwości i strategie implantacji
12:13 Lithix – technologia i pierwsze doświadczenia kliniczne
12:21 IVUS w codziennej praktyce – sizing, plaque morphology, optimization
12:29 AI w optymalizacji stentowania (Boston AI tools)
12:37 Ocena vessel motion i remodeling w obrazowaniu

Sesja case-based

Prowadzenie: Michał Wróbel, Łukasz Pyka

12:45 Lithix Case 1: zwapnienia koncentryczne
13:00 Lithix Case 2: zwapnienia długie/rozsiane – rola Lithix w leczeniu wielu zmian
13:15 Lithix Case 3: zwapnienia w pniu LTW – zastosowanie Lithix
13:30 Bioadaptor / IVUS-guided PCI – ciekawe przypadki

Hands-on IVUS trening (3 stacje, rotacje po 20 min)

Prowadzenie: Michał Hawranek

Stacja 1: Ocena zwapnień (arc, depth, calcium scoring)
Stacja 2: Optymalizacja implantacji stentu (stent expansion, malapposition, edge dissection)
Stacja 3: Ocena pozabiegowa (remodeling, motion, edge issues)

Podsumowanie i panel Q&A

→ Workshop in Polish / Warsztat w j. polskim
Sponsored session/ Sesje sponsorowane

15:00-16:00 Coffee break/ Przerwa kawowa

16:00 – 18:00 WORKSHOP

Creating an Inclusive Environment for LGBTQIA+ Patients and Populations: A Culturally Competent Approach to Preventative Care

Chair: Anthony Dissen, Michał Czapla

→ focus on equipping physicians and healthcare professionals with the knowledge, skills, and dispositions necessary to foster an inclusive, affirming, and culturally competent care environment for LGBTQIA+ patients.

SATURDAY 11.10.2025

09:00 – 10:10 Session 1. Building the Prevention & Intervention Heart Team

Chair: Izabella Uchmanowicz, Shrilla Banerjee

Panel: Christopher Lee

09:00 – 09:12 The global burden of ASCVD: Where are we and what needs to change?

→ overview of the current cardiovascular disease burden and identification of key unmet needs.

Michael Papadakis

09:12 – 09:24 Modifiable risk factors in ASCVD: From knowledge to population impact

→ the significance of classical and novel risk factors, and effective strategies for risk reduction.

09:24 – 09:36 Non-invasive diagnostics in ASCVD: Tools for early detection and future innovation

→ imaging and biomarkers for early identification of high-risk patients.

Marta Kałużna-Oleksy

09:36 – 09:48 Invasive diagnostics and treatment strategies: Evolving concepts in risk-guided intervention

→ role of FFR, iFR, OCT, IVUS, microvascular assessment, and inflammatory diagnostics — today and tomorrow.

Kyriakos Dimitriadis

09:48 – 10:00 Integrating prevention and intervention: Heart Team models, benefits, and challenges

→ how to build an interdisciplinary team linking prevention and intervention — what works and what needs to evolve.

Michał Hawranek

10:00-10:10 Discussion

10:10 – 10:25 Coffee break

10:25 – 11:35 Session 2. From vulnerable plaque to vulnerable patient: Redefining cardiovascular risk

Chair: Michał Hawranek, Vijay Kunadian

Panel: Biljana Parapid

10:26 – 10:38 Defining the vulnerable patient: Systemic risk beyond the lesion

→ who is truly at risk of sudden cardiovascular events? From traditional risk factors to dynamic systemic models.

Aleksander Prejbisz

10:38 -10:50 Vulnerable plaques: What makes a lesion dangerous?

→ anatomical, biological, and functional features of rupture-prone plaques — identification and clinical significance.

10:50 – 11:02 Non-invasive imaging in risk stratification: Can we see the unstable plaque?

→ the role of CTA, CMR, PET and other imaging techniques in detecting unstable plaques and high-risk patients.

11:02 -11:14 Pharmacological stabilization of the vulnerable patient: What works today?

→ plaque-stabilizing drugs: Statins, pcsk9 inhibitors, lp(a)-lowering agents, anti-inflammatory and antiplatelet therapies.

Milovan Petrović

11:14 – 11:26 Can intervention become prevention? Early action to prevent events

→ should we treat non-critical but high-risk lesions? Evidence, controversies, and future directions.

Francesco Saia

11:26-11:35 Discussion

11:35 – 11:50 Coffee break

11:50 – 13:00 Session 3. Core risk drivers in ASCVD: Lipids, inflammation, glucose, and pressure

Chair: Francesco Saia

Panel: Pierre Sabouret, Stephane Carlier, Aleksander Prejbisz

11:51 – 12:03 Dyslipidemia and lipoprotein risk: From LDL to Lp(a)

→ atherogenic lipoproteins as drivers of plaque growth and destabilization.

Pierre Sabouret

12:03 – 12:15 Chronic inflammation in ASCVD: A persistent ignition source

→ low-grade systemic inflammation as a central mechanism of vascular injury.

Marek Gierlotka

12:15 – 12:27 Diabetes and insulin resistance: The metabolic substrate of vascular risk

→ the role of hyperglycemia, oxidative stress, and endothelial dysfunction.

Zbigniew Siudak

12:27 – 12:39 Hypertension and hemodynamic stress: More than just numbers

→ pressure variability and shear stress as contributors to plaque rupture risk.

Rokas Serpytis

12:39 – 12:51 Interventional Treatment for Hypertension Management: Broad application or patient-specific therapy?

12:51 – 13:00 Discussion

13:00 – 13:50 Lunch

13:50 – 15:00 Session 4. Systemic disease and comorbidity: Accelerators of cardiovascular instability

Chair: Sebastian Szmit, Kyriakos Dimitriadis

Panel: Eleni Kletsiou, Carmen Moldovan, Rokas Serpytis, Marek Gierlotka

13:51 – 14:03 The Different Faces of Pulmonary Hypertension

14:03 – 14:15 Autoimmune diseases and inflammatory burden: A hidden cardiovascular threat

→ immune system activation and its impact on endothelium and thrombosis.

Jakub Morze

14:15 – 14:27 Psychosocial risk factors: When the mind fuels the heart

→ sleep disorders, depression, and stress as modulators of vascular inflammation.

Izabella Uchmanowicz

14:27 – 14:39 Cancer, therapy-related inflammation and cardiovascular risk

→ how malignancy and treatments accelerate atherothrombosis.

Sebastian Szmit

14:39 -14:51 What do we know from studies about obesity as a cardiovascular risk factor

Joanna Popiołek-Kalisz

14:51 – 15:00 Discussion

15:00 – 15:15 Coffee break

15:15 – 16:25 Session 5. Precision prevention and future therapies in ASCVD

Chair: Tadeusz Osadnik, Sarita Rao

Panel: Michał Czapla, Anthony Dissen, Ekaterini Lambrinou, Jakub Morze

15:16 – 15:28 Treating obesity as a cardiovascular disease: From weight to risk reduction

→ addressing obesity as an atherogenic condition.

Michał Czapla

15:28 -15:40 Genetics and polygenic risk in ASCVD: Clinical applications and future potential

→ from rare variants to polygenic risk scores and targeted therapies.

Jamal Rana

15:40 – 15:52 Artificial intelligence and predictive modeling in ASCVD prevention

→ AI integration for risk stratification and personalized therapy.

Jacek Niedziela

15:52 – 16:04 Health empowerment and AI for rehabilitation and training

Stephane Carlier

16:04 – 16:16 Thrombotic risk and antiplatelet therapy: Personalized antithrombotic strategies

→ evolving approaches to balance thrombotic and bleeding risks.

16:16 – 16:25 Discussion

16:25 – 16:40 Coffee break

16:40 – 17:50 Session 6. Advanced coronary disease: Managing complex atherosclerosis

Chair: **Michał Hawranek**

Panel: **Jacek Legutko, Mirvat Alasnag, Marta Kałużna-Oleksy**

16:41 – 16:53 Multivessel disease: Is revascularization always the answer?

→ decision-making in diffuse CAD considering anatomy and comorbidities.

16:53 – 17:05 Calcium everywhere: How to treat heavily calcified coronary arteries

→ imaging, atherectomy, and lithotripsy in severe calcification.

Shrilla Banerjee

17:05 – 17:17 Revascularization in left main and bifurcations: Anatomy meets strategy

→ current evidence and controversies.

17:17 – 17:29 Chronic total occlusions: When and why should we still intervene?

→ indications, techniques, and predictors of success.

Maciej Marciniak

17:29 – 17:41 Heart Team strategy in advanced CAD – the role of cardiac surgery

→ procedural planning and follow-up using the Heart Team model.

17:41 – 17:50 Discussion

17:50 – 18:05 Coffee break

18:05 – 19:15 Session 7. Bleeding, vulnerability and complexity: How to treat the unstable patient

Chair: **Vijay Kunadian, Valeria Paradies**

Panel: **Aaysha Cader, Maciej Marciniak, Mirvat Alasnag**

18:06 – 18:18 Treating patients with high bleeding risk: How low can we go?

→ monotherapy, DAPT minimization, and individualized strategies.

Vijay Kunadian

18:18 – 18:30 PCI in complex CCS patients: Frailty, CKD, and anemia

→ decisions in stable but high-risk patients.

Jacek Legutko

18:30 – 18:42 Managing anticoagulation in PCI: AF, VTE, and triple therapy dilemmas

→ strategies for managing doacs, vkas and procedural risks.

Bartosz Hudzik

18:42 – 18:54 Post-PCI algorithm - Heart Team for the complex patient

→ integrating geriatrics, nephrology, internal medicine in interventional care.

18:54 – 19:15 Discussion

SUNDAY 12.10.2025

09:00 – 10:10 Session 8. Destabilized: Hemodynamic collapse and the role of circulatory support

Chair: **Marta Kałużna-Oleksy**

Panel: **Robert J. Gil, Jerzy Sacha, Wiktor Kulickowski**

09:01 – 09:13 The final stage of vulnerability: Identifying the failing cardiovascular system

→ clinical, hemodynamic, and biomarker indicators.

Giulia Masiero

09:13 – 09:25 Stabilizing the unstable: MCS as a bridge to decision, recovery or exit strategy

→ MCS in ACS, cardiogenic shock, and mechanical complications.

09:25 – 09:37 Preventing collapse in high-risk PCI: When to plan for MCS

→ elective support strategies in borderline patients.

Marta Kałużna-Oleksy

09:37 – 09:49 Beyond the heart: How MCS protects the brain, kidneys, and systemic function

→ organ protection and systemic stabilization.

Wiktor Kulickowski

09:49 – 10:01 National Program for the Treatment of Cardiogenic Shock – How to Implement It Effectively

Robert J. Gil

10:01 – 10:10 Discussion

10:10 – 10:25 Coffee break

10:25 – 10:55 Session 9. ESC guidelines in practice: Heart Team in action - Real cases with guidelines approach.
Part 1. Multivessel disease in a diabetic patient: Strategy beyond revascularization – what do the ESC guidelines say?

10:25 – 10:32 Case presentation: Multivessel disease in a diabetic patient: Strategy beyond revascularization

Aaysha Cader

10:32 – 10:42 Revascularization in diabetes

Sarita Rao

10:42 – 10:52 Prevention of atherosclerosis progression and late stent failure

Ulvi Myrzoyev

10:55 – 11:25 Session 9. ESC guidelines in practice: Heart Team in action - Real cases with guidelines approach
Part 2. Bleeding risk vs ischemic benefit: PCI in an octogenarian with AF and CKD – what do the ESC guidelines say?

Chair: **Bartosz Hudzik**

10:55 -11:02 Case presentation: Bleeding risk vs ischemic benefit - PCI in an octogenarian with AF and CKD

Nicola Ryan

11:02 – 11:12 Strategy of revascularization in high bleeding risk patients

11:12 -11:22 Short and long term management of patient after intervention

Ivan Ilic

11:25 – 11:55 Session 9. ESC guidelines in practice: Heart Team in action - Real cases with guidelines approach
Part 3. Young patient with multimorbidity – multilevel atherosclerosis, arrhythmia, and valvular heart disease – what do the ESC guidelines say?

Chair: **Jamal Rana, Mila Kovacevic**

11:25 – 11:32 Case presentation: Young patient with multimorbidity – multilevel atherosclerosis, arrhythmia, and valvular heart disease

Magdalena Dudek

11:32 – 11:42 Multilevel atherosclerosis

Carmen Moldovan

11:42 – 11:52 Heart rhythm disorders

11:55 – 12:10 Coffee break

12:10 – 13:20 Session 10. Decoding HFpEF: From diagnosis to multidisciplinary care and the patient voice

Chair: **Eleni Kletsiou**

Panel: **Izabella Uchmanowicz, Michał Hawranek, Marta Kałużna-Oleksy, Christopher Lee**

12:10 -12:22 A two-phase approach to diagnosing HFpEF: Clinical scores and decision trees

Izabella Uchmanowicz

12:22 – 12:34 The role of heart failure nurses in diagnosing and managing HFpEF

Ercole Vellone



12:34 – 12:46 The multidisciplinary HF Team: Making complex care work for HFpEF

Massimo Piepoli

12:46 – 12:58 Living with HFpEF: What patients need and what they tell us

Ekaterini Lambrinou

12:58 – 13:10 Chronic kidney disease and cardiovascular risk: The cardio-renal continuum

→ uremic toxins, mineral imbalance, and volume overload as atherogenic factors.

13:10 -13:20 Discussion

13:20 – 13:35 Coffee break

13:35 – 14:45 Session 11. Obesity in women

Chair: **Mirvat Alasnag**

Panel: **Izabella Uchmanowicz, Marta Kałużna-Oleksy, Michał Hawranek**

13:35 – 13:47 Obesity and Inflammation as Drivers of Atherosclerotic Cardiovascular Disease: Sex-Specific Risks and Mechanisms

Mirvat Alasnag

13:47 – 13:59 Female-Specific Cardiometabolic Pathways: PCOS, Menopause, and the Inflammatory Cascade

Antonia Sambola

13:59 – 14:11 Obesity Interventions and Their Impact on MACE Reduction: What Works, For Whom, and Why

14:11 - 14:23 Lifestyle and Hormonal Modulation of Cardiovascular Risk in Obese Women

Biljana Parapid

14:23 – 14:35 Beyond Conventional Risk Factors: Priorities in Women's Cardiovascular Health

Valeria Paradies

14:35 – 14:45 Discussion

14:45 – 15:50 Coffee break

15:00 – 16:10 Session 12. The Prevention & Intervention Heart Team model: Putting it all together

Panel: **Izabella Uchmanowicz, Marta Kałużna-Oleksy, Michał Hawranek**

15:00 – 15:12 What we learned about risk and instability in ASCVD

→ summary of biological, anatomical, and clinical risk markers.

Jamal Rana

15:12 – 15:24 The expanding role of interventional cardiology in team-based ASCVD care

→ from proceduralist to strategic leader.

15:24 – 15:36 How to organize a real Heart Team

→ team structure, roles, and collaboration points.

Michał Hawranek

15:36 – 15:48 What's next? The future of prevention and intervention

→ AI, data integration, teleconsultations, and population-level engagement.

Christopher Lee

15:48 – 16:10 Discussion

SUNDAY WORKSHOP

10:25 – 11:55 Case challenge with Shockwave IVL

Chair: Marta Kałużna-Oleksy, Michał Hawranek

Shockwave IVL: Expanding horizons in the treatment of coronary calcification – **Michał Hawranek**

Case 1-5

How to deal with Shockwave-IVL in everyday practice – session summary – **Marta Kałużna-Oleksy**

16:10 – 17:00 Lunch
